Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 01, 2023 -- Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today... | June 1, 2023

Related Keywords

Switzerland , ,Pharvarisnv Stock Exchange ,News ,Information ,Press Release ,Pune ,023 ,Pharvaris ,Company ,Developing ,Mural ,Antagonists ,O ,Treat ,End ,Prevent ,Hereditary ,Ngioedema Phvs Nl00150005y4 ,